Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Volanesorsen - Ionis Pharmaceuticals

Drug Profile

Volanesorsen - Ionis Pharmaceuticals

Alternative Names: IONIS-304801; IONIS-APOCIII; IONIS-APOCIIIRx; ISIS-304801; ISIS-APOCIII; ISIS-APOCIII-Rx; Volanesorsen; Volanesorsen sodium; WAYLIVRA

Latest Information Update: 16 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Akcea Therapeutics; Ionis Pharmaceuticals
  • Class Antihyperlipidaemics; Antisense oligonucleotides; Antisense RNA; Cardiovascular therapies
  • Mechanism of Action Apolipoprotein C-III inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperlipoproteinaemia; Lipodystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hyperlipoproteinaemia type I
  • Phase III Hypertriglyceridaemia; Lipodystrophy

Most Recent Events

  • 06 Nov 2019 Launched for Hyperlipoproteinaemia type I in France, Germany (SC) before November 2019
  • 06 Nov 2019 Ionis Pharmaceuticals plans to launch volanesorsen in European Union countries
  • 07 Aug 2019 Ionis Pharmaceuticals and Akcea Therapeutics intends to launch of volanesorsen for Hyperlipoproteinaemia type I (familial chylomicronaemia syndrome) in Germany in August 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top